279 related articles for article (PubMed ID: 22059955)
1. Insulin sensitisers in the treatment of non-alcoholic fatty liver disease: a systematic review.
Shyangdan D; Clar C; Ghouri N; Henderson R; Gurung T; Preiss D; Sattar N; Fraser A; Waugh N
Health Technol Assess; 2011 Nov; 15(38):1-110. PubMed ID: 22059955
[TBL] [Abstract][Full Text] [Related]
2. Diabetes drugs for nonalcoholic fatty liver disease: a systematic review.
Blazina I; Selph S
Syst Rev; 2019 Nov; 8(1):295. PubMed ID: 31783920
[TBL] [Abstract][Full Text] [Related]
3. Drugs improving insulin resistance for non-alcoholic fatty liver disease and/or non-alcoholic steatohepatitis.
Angelico F; Burattin M; Alessandri C; Del Ben M; Lirussi F
Cochrane Database Syst Rev; 2007 Jan; (1):CD005166. PubMed ID: 17253544
[TBL] [Abstract][Full Text] [Related]
4. Efficacy and safety of anti-hyperglycaemic drugs in patients with non-alcoholic fatty liver disease with or without diabetes: An updated systematic review of randomized controlled trials.
Mantovani A; Byrne CD; Scorletti E; Mantzoros CS; Targher G
Diabetes Metab; 2020 Nov; 46(6):427-441. PubMed ID: 31923578
[TBL] [Abstract][Full Text] [Related]
5. Meta-Analysis of Randomized Controlled Trials of Pharmacologic Agents in Non-alcoholic Steatohepatitis.
Said A; Akhter A
Ann Hepatol; 2017; 16(4):538-547. PubMed ID: 28611274
[TBL] [Abstract][Full Text] [Related]
6. Non-alcoholic fatty liver disease and steatohepatitis: State of the art on effective therapeutics based on the gold standard method for diagnosis.
Mahjoubin-Tehran M; De Vincentis A; Mikhailidis DP; Atkin SL; Mantzoros CS; Jamialahmadi T; Sahebkar A
Mol Metab; 2021 Aug; 50():101049. PubMed ID: 32673798
[TBL] [Abstract][Full Text] [Related]
7. Folic acid supplementation and malaria susceptibility and severity among people taking antifolate antimalarial drugs in endemic areas.
Crider K; Williams J; Qi YP; Gutman J; Yeung L; Mai C; Finkelstain J; Mehta S; Pons-Duran C; Menéndez C; Moraleda C; Rogers L; Daniels K; Green P
Cochrane Database Syst Rev; 2022 Feb; 2(2022):. PubMed ID: 36321557
[TBL] [Abstract][Full Text] [Related]
8. Insulin sensitizers in nonalcoholic fatty liver disease and steatohepatitis: Current status.
Stein LL; Dong MH; Loomba R
Adv Ther; 2009 Oct; 26(10):893-907. PubMed ID: 19921118
[TBL] [Abstract][Full Text] [Related]
9. The Effect of Thiazolidinediones in Polycystic Ovary Syndrome: A Systematic Review and Meta-Analysis of Randomised Controlled Trials.
Abdalla MA; Shah N; Deshmukh H; Sahebkar A; Östlundh L; Al-Rifai RH; Atkin SL; Sathyapalan T
Adv Ther; 2024 Jun; 41(6):2168-2195. PubMed ID: 38683294
[TBL] [Abstract][Full Text] [Related]
10. Newer agents for blood glucose control in type 2 diabetes: systematic review and economic evaluation.
Waugh N; Cummins E; Royle P; Clar C; Marien M; Richter B; Philip S
Health Technol Assess; 2010 Jul; 14(36):1-248. PubMed ID: 20646668
[TBL] [Abstract][Full Text] [Related]
11. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with polycystic ovary syndrome, oligo amenorrhoea and subfertility.
Morley LC; Tang T; Yasmin E; Norman RJ; Balen AH
Cochrane Database Syst Rev; 2017 Nov; 11(11):CD003053. PubMed ID: 29183107
[TBL] [Abstract][Full Text] [Related]
12. [Therapeutic effects of insulin-sensitizing drugs on nonalcoholic fatty liver disease: experiment with rats].
Zhang DM; Zhang GY; Wang T; Zhong HJ; Chen WK
Zhonghua Yi Xue Za Zhi; 2006 May; 86(18):1279-83. PubMed ID: 16796890
[TBL] [Abstract][Full Text] [Related]
13. Nonalcoholic fatty liver disease: current issues and novel treatment approaches.
Lomonaco R; Sunny NE; Bril F; Cusi K
Drugs; 2013 Jan; 73(1):1-14. PubMed ID: 23329465
[TBL] [Abstract][Full Text] [Related]
14. Effects of different insulin sensitisers in the management of polycystic ovary syndrome: A systematic review and meta-analysis.
Melin JM; Forslund M; Alesi SJ; Piltonen T; Romualdi D; Spritzer PM; Tay CT; Pena AS; Witchel SF; Mousa A; Teede HJ
Clin Endocrinol (Oxf); 2024 Feb; 100(2):149-163. PubMed ID: 37933831
[TBL] [Abstract][Full Text] [Related]
15. Effect of incretin therapies compared to pioglitazone and gliclazide in non-alcoholic fatty liver disease in diabetic patients not controlled on metformin alone: An observational, pilot study.
García Díaz E; Guagnozzi D; Gutiérrez V; Mendoza C; Maza C; Larrañaga Y; Perdomo D; Godoy T; Taleb G
Endocrinol Nutr; 2016 May; 63(5):194-201. PubMed ID: 26976710
[TBL] [Abstract][Full Text] [Related]
16. Statins for non-alcoholic fatty liver disease and non-alcoholic steatohepatitis.
Eslami L; Merat S; Malekzadeh R; Nasseri-Moghaddam S; Aramin H
Cochrane Database Syst Rev; 2013 Dec; (12):CD008623. PubMed ID: 24374462
[TBL] [Abstract][Full Text] [Related]
17. Meta-analysis: pioglitazone improves liver histology and fibrosis in patients with non-alcoholic steatohepatitis.
Boettcher E; Csako G; Pucino F; Wesley R; Loomba R
Aliment Pharmacol Ther; 2012 Jan; 35(1):66-75. PubMed ID: 22050199
[TBL] [Abstract][Full Text] [Related]
18. Clinical effectiveness and cost-effectiveness of pioglitazone and rosiglitazone in the treatment of type 2 diabetes: a systematic review and economic evaluation.
Czoski-Murray C; Warren E; Chilcott J; Beverley C; Psyllaki MA; Cowan J
Health Technol Assess; 2004 Apr; 8(13):iii, ix-x, 1-91. PubMed ID: 15038907
[TBL] [Abstract][Full Text] [Related]
19. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement.
Athyros VG; Alexandrides TK; Bilianou H; Cholongitas E; Doumas M; Ganotakis ES; Goudevenos J; Elisaf MS; Germanidis G; Giouleme O; Karagiannis A; Karvounis C; Katsiki N; Kotsis V; Kountouras J; Liberopoulos E; Pitsavos C; Polyzos S; Rallidis LS; Richter D; Tsapas AG; Tselepis AD; Tsioufis K; Tziomalos K; Tzotzas T; Vasiliadis TG; Vlachopoulos C; Mikhailidis DP; Mantzoros C
Metabolism; 2017 Jun; 71():17-32. PubMed ID: 28521870
[TBL] [Abstract][Full Text] [Related]
20. Pharmacological interventions for non-alcohol related fatty liver disease (NAFLD): an attempted network meta-analysis.
Lombardi R; Onali S; Thorburn D; Davidson BR; Gurusamy KS; Tsochatzis E
Cochrane Database Syst Rev; 2017 Mar; 3(3):CD011640. PubMed ID: 28358980
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]